

Electronic cigarettes (ECs): Considerations on pulmonary and cardiological complications associated with their consumption

Cigarros eletrônicos (CEs): Considerações sobre as complicações pulmonares e cardíacas associadas ao seu consumo

Cigarrillos electrónicos (CE): Consideraciones sobre las complicaciones pulmonares y cardíacas asociadas a su consumo

Rosana da Cruz Benito¹, Linconl Agudo Oliveira Benito²

How to cite: Benito RC, Benito LAO. Electronic cigarettes (ECs): Considerations on pulmonary and cardiological complications associated with their consumption. REVISA. 2025 Jul-Set; 14(3): 1660-6. Doi: <https://doi.org/10.36239/revisa.v14.3.p1660a1666>

REVISA

1. Centro Universitário do Distrito Federal. Brasília, Distrito Federal, Brasil.
<https://orcid.org/0000-0002-2881-1193>

2. Universidade de Brasília (UnB), Programa de Pós-Graduação em Ciências e Tecnologias em Saúde. Brasília, Distrito Federal, Brasil.
<https://orcid.org/0000-0001-8624-0176>

Received: 13/04/2025
Accepted: 21/06/2025

Currently, the consumption of smoking devices, considered by society as "vapers," is becoming increasingly common among the younger population, with its use being noted even in the face of legal prohibitions established in society. Some of its attractions can be attributed to various factors, among which stand out its design considered more modern, characterized by presenting innovative and practical engineering for consumption, as well as the possibility of inhaling sweeter aromas and having a more pleasant breath, making its consumption more acceptable with all these strategies for the diverse groups within society.^{1,2,3}

Considered a technological novelty and, given the diversity of flavors and models, electronic cigarettes (ECs), in addition to the various compositions in their constituent structure, the aerosols generated by the heating of these devices, when inhaled, tend to provoke "inflammations" and "hyper-responsiveness" in the airways, posing a risk of developing pulmonary and cardiac diseases. With this new form of addiction, society has been strongly challenged by the paradox of smoking, where on one hand public policies favor campaigns to reduce the consumption of conventional cigarettes, while on the other hand, the popularity of ECs is rising, without proper oversight, leading to indiscriminate use among the younger population.^{6,7,8}

EDITORIAL

This dangerous practice has been favoring not only the emergence of pulmonary and cardiac complications but also sociocultural and socioeconomic harm, since its users usually begin using ECs before the age of twenty, directly interfering with their personal financial expenses.⁶⁻⁸ According to some researchers, and given the enormous growth of this consumer public, who use ECs daily, a higher record of acute respiratory and cardiac complications has been identified, as well as damage to the immune system, in addition to variations in the severity of body-related disorders.⁷⁻⁹

Knowing that the main system affected by EC exposure is the pulmonary system, and considering the complexity of the anatomy and physiology involved in respiration, it normally undergoes oxidative stress promoted by prolonged consumption, since their composition contains some harmful substances to the body.⁶⁻⁹ In this context, among the substances identified in this dangerous process are formaldehyde (CH_2O), acetaldehyde ($\text{C}_2\text{H}_4\text{O}$), heavy metals such as lead (Pb), copper (Cu), silver (Ag), mercury (Hg), and cadmium (Cd), all of which are considered by the International Agency for Research on Cancer (IARC) to be carcinogenic substances.^{6 8 9 23}

Also within this context, propylene glycol ($\text{C}_3\text{H}_8\text{O}_2$) and glycerin ($\text{C}_3\text{H}_8\text{O}_3$) can be found, with concentrations ranging from 16 to 22 mg/ml. They constitute a concerning factor due to their toxicity, associated with the presence of nicotine ($\text{C}_{10}\text{H}_{14}\text{N}_2$) and flavoring agents, the latter being one of the main forms of attraction for the younger population.^{8 9 23} In the case of propylene glycol ($\text{C}_3\text{H}_8\text{O}_2$), it is considered a toxic product and, besides having high chemical content, it is commonly used in the production of polyester resins, food products, liquid detergents, and antifreeze products.^{9 23}

Biochemically, it is also used as a solvent, humectant, and emulsifier in cosmetic products. When combined with glycerin, it is identified as a solvent for nicotine ($\text{C}_{10}\text{H}_{14}\text{N}_2$), forming the base of the liquid to be vaporized, in which these contents in liquid form are converted into aerosols.^{7-9 23} Given the uncontrolled consumption of ECs, researchers report that some findings in radiological exams were able to demonstrate the presence of characteristic pulmonary alterations due to their consumption, based on the symptoms identified in these individuals.⁷⁻¹⁰

Among the known alterations are difficulty breathing (dyspnea), coughing, expectoration of blood from the lower respiratory tract, lungs, trachea, or bronchi (hemoptysis), as well as gastrointestinal involvement, evidenced by nausea, vomiting, and abdominal pain.⁵⁻¹⁰ In more severe cases, increased heart rate (tachycardia) and rapid breathing, i.e., a respiratory rate above normal (tachypnea), are also verified.¹⁰

In this sense, and in addition to these symptoms, recent studies point out that medium- and long-term continuous use of ECs may lead to the emergence of adverse cardiovascular problems, since nicotine ($\text{C}_{10}\text{H}_{14}\text{N}_2$) present in these devices activates the sympathetic nervous system (SNS).^{11 12} With this activation, this complex phenomenon physiologically causes an increase in heart rate, blood pressure ($\uparrow\text{BP}$), and oxidative stress. Thus, the chemical components of which they are composed favor the formation of atherosclerotic plaques and increase the risk of developing a stroke.^{11 12}

It is verified that the “false perception of safety” generated among EC users leads many consumers to indiscriminate use, considering that some

research indicates that replacing conventional cigarettes with ECs reduces exposure to certain toxic substances.^{13 14} However, catecholamines (CA) are also identified as hormones and neurotransmitters that control the central nervous system (CNS) and the autonomic nervous system (ANS). Their levels tend to increase, leading to higher cardiac load and cumulative damage to cardiovascular health.^{13 14}

Among these data, the early development of arrhythmias can be pointed out when these users already have a genetic predisposition for the emergence of cardiovascular diseases.^{13 14} In this context, the “E-cigarette or Vaping product use-Associated Lung Injury” emerged in mid-2019, better known as “EVALI,” also called “VAPI” (vaping-associated lung injury). It is classified as an acute or subacute disease that can be severe and life-threatening, characterized by a set of respiratory and gastrointestinal symptoms.¹⁵⁻¹⁷

In this sense, and according to some researchers, the causes and mechanisms leading to the diagnosis of “EVALI” are still not precise; however, histopathological findings have identified the presence of diffuse alveolar damage associated with bronchiolocentric pneumonia and/or acute fibrinous and organizing pneumonia (AFOP).¹⁶⁻¹⁸ In addition, diagnosed cases may progress to respiratory failure, requiring oxygen (O₂) support, orotracheal intubation (OTI), and in more severe cases, treatment with mechanical ventilation (MV).¹⁶⁻¹⁸

Regarding the gastrointestinal system, the development of inflammatory processes tends to alter its microbiota, causing fragility of the intestinal membrane and, consequently, favoring the onset of several chronic, inflammatory, and cardiovascular diseases.^{8-10 19 20} In this context, changes in microbial balance and diversity are verified. These findings are of great importance for medical and clinical analysis, as they corroborate the identification of harmful effects related to the indiscriminate use of these devices.^{9 10 19 20}

Still in this context, and considering a pulmonary pathology that does not present specific symptoms for an accurate diagnosis, such as “EVALI,” it is necessary to correlate the findings with those identified in computed tomography (CT) scans.^{21 22} Thus, it is important to correlate imaging exams with verified clinical signs and symptoms, such as cough, malaise, difficulty breathing, as well as the history of continuous medium- or long-term EC use, making these findings essential for a positive and unquestionable result.^{9 10 21 22}

When radiographic examinations reveal “diffuse or multifocal ground-glass opacities,” these become indicative of pulmonary tissue inflammation and edema, especially in the lung lobes. This characterizes a possible positive diagnosis for “EVALI” and allows for the adoption of appropriate therapeutic approaches for proper treatment.²⁰⁻²² In this context, it is important to highlight Collegiate Board Resolution (RDC) No. 46/2009 of the Brazilian Health Regulatory Agency (ANVISA), which “prohibits the commercialization, importation, and advertising of electronic smoking devices, identified as ECs.”²³⁻²⁵

In contrast, the commercialization and importation of the fourth (4th) generation of ECs has already been identified, with acquisition values ranging from approximately R\$ 60.00 to R\$ 680.00. However, many adherents of this new smoking modality declare permission for the use of these devices, claiming that inhalations do not carry smoke but rather “vapor,” since there is no burning of tobacco and tar. This demonstrates consumers’ lack of awareness regarding the

risks of their consumption.²⁶⁻²⁸ In this context, it is possible to understand that the indiscriminate emergence and consumption of ECs stimulated a “false perception” of a “safe consumption habit,” in addition to a “positive image” when compared to conventional cigarettes and the numerous smoking products currently commercialized.²⁴⁻²⁸

Despite the existence of bans on the commercialization of ECs in Brazil, health policies for the prevention of smoking product consumption, ANVISA Resolution No. 46/2009, among other efforts, there is still a high demand for the acquisition and consumption of ECs, mostly by new consumers belonging to younger age groups who are unaware of the direct and indirect risks posed by these devices.²⁴⁻²⁸

Acknowledgment

This study was funded by the authors themselves.

References

1. De Almeida ABOA de; Fachin LP. Uso de cigarro eletrônico e EVALI: revisão sistemática. Braz. J. Hea. Rev. 2023;6(4):16383-16394. DOI: <https://doi.org/10.34119/bjhrv6n4-186>.
2. Nascimento CO, Ferle Filho D. Lesões pulmonares associadas ao uso de cigarro eletrônico ou vaping (EVALI): uma revisão de literatura. 2022. Monografia (Graduação em Medicina) - Faculdade de Ciências Biomédicas de Cacoal (FACIMED), Cacoal, 2022. DOI: [10.29327/41149165](https://doi.org/10.29327/41149165).
3. Filho ARSB, *et al.* Cigarro eletrônico: Malefícios e comparação com o tabagismo convencional. Braz. J. Hea. Rev., 2021; 4(4):15898-15907. DOI: [10.34119/bjhrv4n4-119](https://doi.org/10.34119/bjhrv4n4-119).
4. Chaumont M, *et al.* Fourth generation cigarette vaping induces transient lung inflammation and gas exchange disturbances: results from two randomized clinical trials. Am J Physiol Lung Cell Mol Physiol. 2019;316(5):L705-L719. DOI: [10.1152/ajplung.00492.2018](https://doi.org/10.1152/ajplung.00492.2018).
5. Antoniewickz L, *et al.* Acute effects of electronic cigarette inhalation on the vasculature and the conducting airways. Cardiovascular Toxicology. 2019; 19: 441-450. DOI:[10.1007/s12012-019-09516-x](https://doi.org/10.1007/s12012-019-09516-x).
6. Menezes AMB, Wehrmeister FC, Sardinha LMV, Paula P do CB de, Costa T de A, Crespo PA, Hallal PC. Uso de cigarros eletrônicos e narguilés no Brasil: um cenário novo e emergente. O estudo Covitel, 2022. J Bras Pneumol. 2023;49(1):e20220290. DOI: [10.36416/1806-3756/e20220290](https://doi.org/10.36416/1806-3756/e20220290).
7. Bertoni N, Szklo AS. Dispositivos eletrônicos para fumar nas capitais brasileiras: prevalência, perfil de uso e implicações para a Política Nacional de Controle do Tabaco. Cad. Saúde Pública. 2021;37(7):e00261920. DOI: [10.1590/0102-311X00261920](https://doi.org/10.1590/0102-311X00261920).
8. Glantz SA, Bareham DW. E-Cigarettes: Use, Effects on Smoking, Risks, and Policy Implications. Annu Rev Public Health. 2018;39:215-235. DOI: [10.1146/annurev-publhealth-040617-013757](https://doi.org/10.1146/annurev-publhealth-040617-013757).
9. Ali N, Xavier J, Engur M, Mohanan PV, De la Serna JB. The impact of e-cigarette exposure on diferente organ systems: A review of recente evidence and future perspectives. J Hazard Mater. 457:131828. DOI: [10.1016/j.jhazmat.2023.131828](https://doi.org/10.1016/j.jhazmat.2023.131828).

10. Winnicka L, Shenoy MA. EVALI and the pulmonary toxicity of electronic cigarettes: a review. *J Gen Intern Med*. 2020;35(7):2130-2135. DOI: [10.1007/s11606-020-05813-2](https://doi.org/10.1007/s11606-020-05813-2).
11. Chaumont M, *et al*. Differential effects of e-cigarette on microvascular endothelial function, arterial stiffness and oxidative stress: A randomized crossover trial. *Scientific reports* 8. 2018;8(1):10378. DOI: <https://doi.org/10.1038/s41598-018-28723-0>.
12. Gonçalves ACM, *et al*. Os impactos do uso de cigarro eletrônico no sistema cardiovascular: uma revisão da literatura. *Revista Contemporânea*. 2024;4(8):e5304. DOI: <https://doi.org/10.56083/RCV4N8-011>.
13. Franzen KF, *et al*. E-cigarettes and cigarettes worsen peripheral and central hemodynamics as well as arterial stiffness: A randomized, double-blinded pilot study. *Vasc Med*. 2018;23(5):419-425. DOI: [10.1177/1358863X18779694](https://doi.org/10.1177/1358863X18779694).
14. Oliveira VH, Do Nascimento Júnior, VP, De Araújo BC. O uso de cigarro eletrônico por jovens e efeitos adversos ao sistema cardiovascular. *Research, Society and Development*. 2022;11(4): e56811427886. DOI: <http://dx.doi.org/10.33448/rsd-v11i4.27886>.
15. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Cigarros eletrônicos: o que sabemos? Estudo sobre a composição do vapor e danos à saúde, o papel na redução de danos e no tratamento da dependência de nicotina. 1. ed. Rio de Janeiro: INCA, 2016. 120p. Disponível em: [\[https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//cigarros-eletronicos-oque-sabemos.pdf\]](https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//cigarros-eletronicos-oque-sabemos.pdf). Acesso em: 21 abri. 2025.
16. Smith ML, *et al*. Vaping-related lung injury. *Virchows Archiv*. 2021;478(1): 81-88. DOI: [10.1007/s00428-020-02943-0](https://doi.org/10.1007/s00428-020-02943-0).
17. Son Y, Mainelis G, Delnevo C, Wackowski OA, Schwander S, Meng Q. Investigating E-Cigarette particle emissions and human airway depositions under various E-Cigarette-use conditions. *Chem Res Toxicol*. 2019;33(2):343-352. DOI: [10.1021/acs.chemrestox.9b00243](https://doi.org/10.1021/acs.chemrestox.9b00243).
18. Kalininskiy A, Bach CT, Nacca NE, Ginsberg G, Marraffa J, Navarette KA, McGraw MD, Croft DP. E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. *Lancet Respir Med*. 2019;7(12). 1017-1026. DOI: [10.1016/S2213-2600\(19\)30415-1](https://doi.org/10.1016/S2213-2600(19)30415-1).
19. Sharma A, *et al*. E-cigarettes compromise the gut barrier and trigger inflammation. *Isience*. 2021;24(2):102035. DOI: [10.1016/j.isci.2021.102035](https://doi.org/10.1016/j.isci.2021.102035).
20. Wu BG, *et al*. The effect of E-cigarettes on the gut microbiome. In: TP64. TP064 Tobacco Product Exposures and Respiratory Health. American Thoracic Society. 2021. p. A3098-A3098.
21. Kligerman S, *et al*. Radiologic, pathologic, clinical, and physiologic findings of electronic cigarette or vaping product use-associated lung injury (EVALI). *Radiology*. 2020;294(3):491-505. DOI: [10.1148/radiol.2020192585](https://doi.org/10.1148/radiol.2020192585).
22. Sreedharan S, *et al*. Radiological findings of e-cigarette or vaping product use associated lung injury: A systematic review. *Heart Lung*. 2021; 50(5):736-741. DOI: [10.1016/j.hrtlng.2021.05.004](https://doi.org/10.1016/j.hrtlng.2021.05.004).

23. Salzman GA, Alqawasma M, Asad H. Vaping associated lung injury (EVALI): An explosive United States epidemic. *Mo Med*. 2019;116(6):492-496.
24. King BA, Jones CM, Baldwin GT, Briss PA. The EVALI and Youth Vaping Epidemics -Implications for Public Health. *N Engl J Med*. 2020; 382(8):689-691. Doi: [10.1056/NEJMp1916171](https://doi.org/10.1056/NEJMp1916171).
25. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada -RDC nº 46, de 28 de agosto de 2009. Proíbe a comercialização, a importação e a propaganda de quaisquer dispositivos eletrônicos para fumar, conhecidos como cigarro eletrônico. Diário Oficial da União. 2009. Disponível em: [\[http://portal.anvisa.gov.br/documents/10181/2718376/RDC_46_2009_COMP.pdf/2148a322-03ad-42c3-b5ba-718243bd1919\]](http://portal.anvisa.gov.br/documents/10181/2718376/RDC_46_2009_COMP.pdf/2148a322-03ad-42c3-b5ba-718243bd1919). Acesso em: 21 abril. 2025.
26. Aguiar G dos S, *et al*. Uso de cigarro eletrônico: efeitos e riscos – revisão integrativa de literatura. *Revista Científica Multidisciplinar Núcleo do Conhecimento*. 2022;(4):22-35. DOI: [10.32749/nucleodoconhecimento.com.br/saude/cigarro-eletronico](https://doi.org/10.32749/nucleodoconhecimento.com.br/saude/cigarro-eletronico).
27. Healthy Children. Org. Powered by Pediatricians. Trusted by parentes. From the American Academy of Pediatrics. Safety & Preventions. Healthy Children. Safety & Prevention. At Home. Liquid Nicotine Used in E-Cigarettes Can Kill Children. Available in [\[https://www.healthychildren.org/English/safety-prevention/at-home/Pages/Liquid-Nicotine-Used-in-E-Cigarettes-Can-Kill-Children.aspx\]](https://www.healthychildren.org/English/safety-prevention/at-home/Pages/Liquid-Nicotine-Used-in-E-Cigarettes-Can-Kill-Children.aspx). Acesso em: April 21, 2025.
28. Síndico Legal. Com. Leis e Gestão Condominial. A proibição do cigarro eletrônico. Variedades. 2022. Disponível em: [\[https://sindicolegal.com/a-proibicao-do-cigarro-eletroni-co/\]](https://sindicolegal.com/a-proibicao-do-cigarro-eletroni-co/). Acesso em: 21 abril. 2025.

Agradecimento

Esse estudo foi financiado pelos próprios autores.

Referências

1. El Meligy OAES, Alamoudi NM, Allazzam SM, El-Housseiny AAM. Biodentine™ versus formocresol pulpotomy technique in primary molars: a 12-month randomized controlled clinical trial. *BMC Oral Health*. 2019;7(19)1-3. DOI: [10.1186/s12903-018-0702-4](https://doi.org/10.1186/s12903-018-0702-4).
2. Li Y, Sui B, Dahl C, Bergeron B, Shipman P, Niu L, Chen J, Tay FR. Pulpotomy for carious pulp exposures in permanent teeth: A systematic review and meta-analysis. *J Dent*. 2019; 84:1-8. DOI: [10.1016/j.jdent.2019.03.010](https://doi.org/10.1016/j.jdent.2019.03.010).
3. Paula AB, Laranjo M, Marto C-M, Paulo S, Abrantes AM, Fernandes B, et al.. Evaluation of dentinogenesis inducer biomaterials: an in vivo study. *J Appl Oral Sci [Internet]*. 2020;28:e20190023. DOI: <https://doi.org/10.1590/1678-7757-2019-0023>
4. Oliveira JFC, Marques BM, Coutinho TCL. Materiais utilizados na pulpotomia em dentes decíduos: uma revisão de literatura. *Revista Fluminense De Odontologia*; 2017;23(47):45-52. DOI: <https://doi.org/10.22409/ijosd.v1i47.348>

5. Munhaes AB, Souza JAS. Perda dental precoce em Odontopediatria: Etiologia, Possíveis Consequências e Opções Terapêuticas. REASE [Internet]. 31º de maio de 2022 ;8(5):2135-49. DOI: <https://doi.org/10.51891/rease.v8i5.5622>
6. Carvalho WC, Lindoso TKN, Thomes CR, Silva TCR, DIAS ASS. Cárie na primeira infância: Um problema de saúde pública global e suas consequências à saúde da criança. Revista Fluminense de Odontologia. 2022;58(2):57-65. DOI: <https://doi.org/10.22409/ijosd.v2i58.50804>
7. Kola SR, Reddy NV, Sneha T, Reddy MA, Niharika P, Kumar PJ. A histopathological comparison of pulpal response to formocresol and sodium hypochlorite used as pulpotomy medicaments: In primary teeth – A clinical trial. J Indian Soc Pedod Prev Dent. 2019 ;37(2):198-204. DOI: 10.4103/1319-2442.261333.
8. Monteiro MHDA, Fraga SAPM. Fitoterapia na prática clínica odontológica: produtos de origem vegetal e fitoterápicos. Revista Fitos. 2021; 15(1): 58-77. DOI 10.32712/2446-4775.2021.1102
9. Araujo ECE, Valois EC, Ferreira VM. **Biografia do Bacuri (Platonia insignis Mart.)**. Folhetos. Embrapa Meio-Norte. Documentos, n. 43, 2022 [Internet]. Disponível em: <https://ainfo.cnptia.embrapa.br/digital/bitstream/item/36438/1/Doc43.pdf>. Acesso em: 10 fev. 2025.
10. Ribeiro JF, Figueiredo MLF, Carvalho ALM, Sousa Neto BP. Pharmacological actions of bacuri butter (Platonia insignis Mart.): an integrative review. Rev Rene. 2021;22:e59963. DOI: <https://doi.org/10.15253/2175-6783.20212259963>
11. Lima SKR, Coêlho AG, Lucarini M, Durazzo A, Arcanjo DDR. The Platonia insignis Mart. as the Promising Brazilian ‘Amazon Gold’: The State-of-the-Art and Prospects. Agriculture. 2022; 12(11):1827. DOI : <https://doi.org/10.3390/agriculture12111827>

Correspondent Author

Lincoln Agudo Oliveira Benito
SEPN 707/907, Via W 5 Norte, Campus
Universitário. ZIP: 70790-075. Asa Norte.
Brasília, Distrito Federal, Brasil.
lincolnbenito@yahoo.com.br